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ABSTRACT 
A cannabinoid refers to any natural or synthetic compound that interacts with the 
CB1 and CB2 receptors. There are currently three different groups of cannabinoids: 
endogenous cannabinoids, phytocannabinoids and synthetic cannabinoids. The most 
common phytocannabinoid is delta-9-tetrahydrocannabinol (THC), which is the active 
component in the Cannabis sativa or marihuana plant1–3. Two examples of synthetic 
cannabinoids that are present in case reports from 2012 to 2018 are AB-FUBINACA and 
AB-PINACA4–7. 
THC and synthetic cannabinoids are commonly encountered drugs in forensic 
toxicology cases, therefore, being able to extract these compounds and their metabolites is 
imperative for toxicological interpretation. There are a variety of commercially available 
sample preparation techniques for these analytes. Companies such as UCT, Biotage, 
Millipore-Sigma, Tecan, and Thermo Fisher Scientific manufacture these products. The 
focus of this research was to evaluate these techniques for their cleanliness, efficiency and 
cost effectiveness. Sample preparation techniques are designed to remove the different 
components of the matrix and other prescription or illicit substances present in the sample 
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that could interfere with the assay, increase the analyte recovery, extraction efficiency, 
decrease variability, and clean-up the sample to allow for less instrument downtime and 
longer column life8. This study focused on comparing a liquid-liquid extraction (LLE), 
solid phase extraction (SPE), and supported liquid extraction (SLE). 
The primary purpose of this study was to develop and validate the three above 
mentioned sample preparation techniques for the analysis of THC, 11-hydroxy-THC, 11-
nor-9-carboxy-THC (THCCOOH), AB-FUBINACA, AB-FUBINACA metabolite 3, and 
AB-PINACA in blood and urine.  
Parameters assessed followed Academy Standards Board (ASB) Standard 036, 
Standard Practices for Method Validation in Forensic Toxicology, including recovery, 
suppression, and matrix effects. 
For urine and blood analysis, the calibration range was determined to be 1 ng/mL 
to 50 ng/mL for all three techniques. Urine recovery was highest for the LLE method, with 
all compounds having a recovery greater than 50%. The SLE method had the lowest LOQ 
results for urine, with 0.5 ng/mL for 11-hydroxy-THC and THCCOOH, 0.75 ng/mL for 
THC, AB-FUBINCA and AB-FUBINACA metabolite 3, and 1 ng/mL for AB-PINACA. 
Ion suppression was reduced using the SLE method for urine along with having the shortest 
sample preparation time of 1 hr for up to 48 samples.  
For blood analysis, the LLE method had the greatest recovery of all analytes. The LLE 
method also had reduced suppression and matrix effects compared to the SPE method. 
Sample preparation was shorter for the SPE method, consuming 2 hrs for an average 
sample batch, compared to 4 hrs for the LLE method, which included a 2 hr freezing step.  
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In conclusion, for urine analysis, all three sample preparation techniques were 
acceptable for the analysis of THC, synthetic cannabinoids, and their metabolites, with the 
SLE method being the preferred method. For blood analysis a LLE and SPE method were 
developed and are adequate for the analysis of THC, synthetic cannabinoids, and their 
metabolites, with the LLE method being the preferred method.  
viii 
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1.1 Cannabinoid Background 
The name cannabinoid was originally applied to naturally occurring C21 aromatic 
hydrocarbon compounds that can be found in the Cannabis sativa plant 9. A cannabinoid 
now refers to any natural or synthetic compound that interacts with the same receptors in 
the human body as the Cannabis sativa compounds 9. The human body consists of two 
receptors that belong in the G-protein class, CB1 and CB2, which are found in the human 
brain and give rise to effects on the central nervous system 1,10–12. CB2 receptors are also 
located in the periphery, predominantly in the immune system 13. These two receptors are 
the binding sites for cannabinoids 1,10–12. Some cannabinoids, such as cannabinol have a 
greater affinity for binding to the CB2 receptor versus the CB1 receptor, influencing the 
different effects cannabinoids have on the human body 13. The different cannabinoids that 
react with these endogenous cannabinoid receptors can be broken up into three different 
groups. The first group are the endogenous cannabinoids, such as anandamide and 2-
archidonylgylercol12,14. The next group of cannabinoids are phytocannabinoids 2. These are 
naturally occurring cannabinoids found in plants. The common source of 
phytocannabinoids is the Cannabis sativa, or marihuana plant, which contains hundreds of 
cannabinoids within the plant material 2. The final group of cannabinoids are synthetic 
cannabinoids. These compounds do not occur naturally, either in the body or in nature, and 
must be synthesized. 
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1.2 NFLIS Reports 
The National Forensic Laboratory Information System (NFLIS) collects forensic 
analysis data from across the United States of America (USA) at the local, regional, and 
national level. This data is then compiled to give a comprehensive look at the drug use 
picture in the USA.  
Early use of Cannabis sativa began with recreational or medicinal uses 1,2,15. 
Cannabis was once the most commonly abused drug in the world but was surpassed by 
methamphetamine in 2017 1,15,16. The NFLIS-Drug 2017 Annual Report and the NFLIS-
Drug 2018 Midyear Report show that cannabis and THC are the second most commonly 
reported drug in forensic cases in the United States 16,17. In the 2018 Midyear Report, 
cannabis and THC account for 22.57% of the total drug cases reported, while the 2017 
Annual Report shows cannabis and THC accounting for 21.76% of the total drug cases 
reported 16,17. Since 2009, the number of cases reported to NFLIS have been decreasing 
with the highest number of cases being reported in the Northeast and Midwest regions 16. 
Cases in which cannabis and THC may be reported include driving under the influence, 
work place drug testing and postmortem cases 1. 
In NFLIS Special Report: Synthetic Cannabinoids and Synthetic Cathinones 
reported to NFLIS for 2013 – 2015, AB-FUBINACA and AB-PINACA were in the top 
four synthetic cannabinoids reported 7. AB-FUBINACA consisted of 11.69% of the total 
synthetic cannabinoid cases reported for 2013 – 2015 while AB-PINACA accounted for 
8.84% 7. For both compounds, there was an increase in the number of cases reported from 
3 
2013 to 2014, while the number decreased from 2014 to 2015 7. The case decrease falls 
along with the scheduling of AB-FUBINACA and a multitude of other synthetic 
cannabinoids in 2014 4. In the 2017 Annual Report for NFLIS AB-FUBINACA was the 
number four most commonly reported drug in the synthetic cannabinoids drug group, 
bringing in 772 of the 24,501 cases reported 16. In the Midyear Report for 2018 AB-
FUBINACA has seen a decrease in the number of cases reported with only 46 of 10,598 
synthetic cannabinoid cases reported 17. 
 
1.3 Cannabis sativa 
The use of Cannabis sativa for its euphoric and psychotomimetic effects, dates back 
at least 5,000 years beginning in Central and Northeast Asia then spreading worldwide 1–
3,15. Throughout history, the uses of cannabis has ranged from recreational to medicinal to 
religious 1,2,15.  
Cannabis sativa contains over 400 natural chemicals ranging from cannabinoids, 
nitrogenous compounds, amino acids, hydrocarbons, flavonoids, alkaloids, and terpenes 
1,2,14. In 1898 and 1899 the first pure cannabinoid to be isolated from cannabis occurred. 
This compound was cannabinol 14. Of these 400 compounds, not all produce an effect on 
the body while others produce a range of effects. The cannabinoid with the most 




 In 1964, the structure of THC was determined 2,3,14. THC is an acidic and 
lypophilic terpenoid with a pKa of 10.6. 2,14,18,19. 1,18. Extraction of THC is made difficult 
due to it being a terpenoid, which are compounds composed of a hydrocarbon backbone, 
which can be modified by the addition of different functional groups and different 
orientations. These numerous modifications in structure lead to a tedious separation 
process 14. THC consists of a tricyclic body and a five-carbon chain, totaling 21 carbons 1 
(Figure 1). There are two numbering systems leading to the delta (D)-1 (D1) and the D9 
naming, in which initial discovery and naming followed the D1 numbering system, while 
more recent work uses the D9 numbering system 3. In 1971 THC was placed under the 
Controlled Substances Act (CSA) as a Schedule 1 drug, which are drugs that have no 
currently accepted medical applications and a high potential for abuse 20.   
 
1.4 Synthetic Cannabinoids 
 Synthetic cannabinoids are compounds that have been synthesized in a laboratory 
and bind to the two cannabinoid receptors 4,21. These compounds, were initially developed 
by John W. Huffman to study the biological mechanisms of the cannabinoid receptor 
system as well as study novel compounds for therapeutic uses 4,21. Synthesis was conducted 
at universities and pharmaceutical companies. These compounds currently have no 
accepted medical uses in the United States 4.  
Synthetic cannabinoids are dissolved in solvents and then applied to plant material 
and dried, or used in e-cigarette appliances 4,21. The most common route of administration 
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of these substances is smoking 4,21. Initial marketing and selling began in Europe as herbal 
incenses, and began appearing in the United States as early as 2008 4,21. Other names 
associated with synthetic cannabinoids, include but are not limited to Spice, K2, Blaze, 
Paradise, Spike, and Black Magic, while they may also be sold under pretext such as 
potpourri or herbal incense 4. Other marketing includes labeling as “legal alternative to 
marijuana” and “legal high” or “not for human consumption” 4,21. The Drug Enforcement 
Agency (DEA) has been scheduling different synthetic cannabinoids as their popularity in 
case reports increases to protect the public’s health and safety 4. The vast majority of these 
compounds are scheduled as Schedule 1 compounds under the CSA. Two of these 
compounds to be scheduled under the CSA and appear on the National Forensic Laboratory 
Information System (NFLIS) annual reports are AB-FUBINACA and AB-PINACA. 
 
1.4.1 AB-FUBINACA 
 AB-FUBINACA was first synthesized by Pfizer Inc. in 2009 and is classified as an 
indazole compound 6,22. The chemical name for AB-FUBINACA is N-(1-amino-3-methyl-
1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 16,17,23 (Figure 1). The 
emergency temporary scheduling of AB-FUBINACA as a Schedule 1 compound under the 
CSA occurred in 2014 24. In 2016 the DEA permanently scheduled AB-FUBINACA as a 
Schedule 1 substance under the CSA 25. Like THC, AB-FUBINACA binds to the CB1 and 
CB2 receptors in the human body and produce similar effects, however these effects may 




 AB-PINACA or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide, is classified as a pentyl indazole and was originally synthesized by Pfizer 
Inc. in 2009 4–6 (Figure 1). It has similar psychoactive effects as THC as it acts on the same 
CB1 and CB2 receptors. Like AB-FUBINACA, the effects may be more severe than those 
of THC 5. From 2010 to 2014, NFLIS reported 3,783 cases, with other agencies reporting 
at least three deaths and multiple overdoses that led to emergency hospital visits 4. In 2015 
the DEA emergency scheduled AB-PINACA as a Schedule 1 on the CSA 5. Two years 
later AB-PINACA was permanently scheduled as a Schedule 1 under the CSA 26. 
 
1.5 Pharmacokinetics and Pharmacodynamics 
1.5.1 Use and Effects 
 THC is a psychoactive substance and its common route of administration is by 
smoking but can also be used orally 1,27–29. It also acts on the central nervous system as a 
depressant 1. The behavioral effects of THC include feeling euphoric, relaxed, an altered 
time perception, lack of focus and memory may be impaired. The person may also 
hallucinate, experience panic attacks, paranoia, and mood swings 1,3. Physical effects 
include impaired movement, slower reaction time and increased appetite 1. 
 A study by NMS Labs and Hartford Healthcare looked at different cases involving 
the ingestion of AB-FUBINACA. In all cases, patients believed they were ingesting 
“Molly”. The physical effects reported included sedation, tachycardia, hypothermia, 
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seizures, while the mental effects included unresponsiveness and an altered mental status 
30. These reports expressed the different toxic effects AB-FUBINACA may cause after use. 
In vitro and in vivo studies show that AB-PINACA is 2 to 14 times more potent 
than THC when acting on the CB1 and CB2 receptors 5. Studies show that AB-PINACA 
is a full agonist for the cannabinoid receptors 5. The effects include nausea, hallucinations, 
anxiety, paranoia, confusion, lethargy, tachycardia, and acute kidney failure to name a few 
symptoms 5. Cases reporting the presence of AB-PINACA include motor vehicle accidents 
leading to death and impaired driving cases, delirium, loss of consciousness and seizures5. 
 
1.5.2 Metabolism and Concentration 
The main route of metabolism for THC in the human body consists of two phases. 
The first phase is hydroxylation in which the final product is 11-hydroxy-THC, an active 
metabolite 1,28,31. The second metabolite is not active and is formed by oxidation, creating 
11-nor-9-carboxy-THC (THCCOOH) 1,31. When analyzing blood levels, THC appears 
rapidly in the blood after smoking, with peak levels between 4.8 to 10.2 minutes (min) at 
levels of 50 to 129 ng/mL for a low dose of 1.75% THC and 76 to 267 ng/mL for a high 
dose of 3.55% THC 1,31. The concentration decreases rapidly after the peak blood 
concentration but is still detectable up to 12 hours (hr) after smoking 31. Peak 11-hydroxy-
THC levels in blood occurred at 13.5 min with concentrations of 6.7 ng/mL for a low dose 
of 1.75% THC and 7.5 ng/mL for a high dose of 3.55% THC, with 11-hydroxy-THC no 
longer being detected before THC 31. Unlike THC and 11-hydroxy-THC, the THCCOOH 
metabolite concentration levels plateaued once reaching peak blood levels 31. Initial 
8 
detection time for THCCOOH is slower compared to THC and 11-hydroxy-THC, however 
once detected, the level is typically higher than 11-hydroxy-THC with the peak plateau 
levels ranging from 32 to 240 min after smoking 31. Peak levels averaged 24.5 ng/mL for 
a low dose of 1.75% THC and averaged 54 ng/mL for a high dose of 3.55% THC 31. 
Detection of THCCOOH ranged from 48 to 168 hr after smoking for a lower initial THC 
dose, while a higher THC dose ranged from 72 to 168 hr after smoking, with a slow decline 
in concentration as compared to THC and 11-hydroxy-THC 31. With the legalization of 
marihuana both medically and recreationally the THC potency has increased, with average 
levels as high as 20.59% in 2017 32. Conversely, in 2014, the average percentage of THC 
was 11.84% 2. It has been shown that THC, 11-hydroxy-THC, and THCCOOH display 
“low to moderate” levels of postmortem redistribution, with the redistribution increasing 
as the postmortem interval increases 18. The postmortem concentration of THC, 11-
hydroxy-THC, and THCCOOH ranged from 0.5 to 50.5 ng/mL, 0.5 to 11.1 ng/mL, and 0.5 
to 107.6 ng/mL respectively 18. 
While the parent compound, AB-FUBINACA, may be detected in human blood or 
urine, the metabolites are predominately found in urine. AB-FUBINACA concentrations 
have been detected as low as 5.6 ng/mL in serum 33. Due to the control status of AB-
FUBINACA, metabolism studies must be carried out in vitro for humans or use an in vivo 
mouse model. The most common metabolite is AB-FUBINACA metabolite 3, which is an 
amide hydrolysis compound 23.  
A study completed in the state of Washington looked at reported concentration 
levels of AB-PINACA from impaired driving cases 34. The levels detected were determined 
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using blood samples from 25 different cases, and ranged in concentration from 0.6 to 41.3 
ng/mL 34. Of the 25 cases, five cases also reported the presence of other drugs along with 
AB-PINACA. One of the five cases contained THCCOOH with a concentration of 7.3 
ng/mL, while the other four cases all contained such as AM-2201, JWH-210, THC, 
THCCOOH, MAM-2210, JWH-018, JWH-019, JWH-091 and JWH-250, ranging in 
concentrations of 0.2 ng/mL to 3.2 ng/mL 34. 
 
Figure 1. Chemical Structures of six analytes of interest 
 
1.6 Sample Preparation Techniques 
1.6.1 Purpose 
 Removing compounds of interest from a given matrix is important in forensic 
toxicology. Due to the complexity of matrices, such as blood and urine, the ability to clean 
up a sample and extract the analytes of interest while leaving interferences behind is 
critical. Blood is composed of plasma, red blood cells, white blood cells, and platelets 35–
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37. The plasma component makes up around 55% to 60% of blood and is composed of 
water, sugars, lipids, salts, and proteins such as albumin, enzymes, and clotting factors 
8,36,37. Urine’s composition consists of urea, creatinine, uric acid, phosphate, sulfate, 
chloride, sodium and potassium ions, and a small amount of proteins and lipids 8,38. Sample 
preparation techniques are designed to remove these different components of the matrix 
that may interfere, along with interferences due to other drugs present in the sample, , 
increase the analyte recovery, decrease variability, and protect the instrument allowing for 
less instrument downtime and longer column life 8. 
 There are a multitude of sample preparation techniques, beginning with the simplest 
technique of dilute and shoot, and moving into more complex extractions such as 
phospholipid depletion, protein precipitation, liquid-liquid extractions (LLE), solid phase 
extractions (SPE), solid phase microextractions, supported liquid extractions (SLE), and 
disposable pipette extractions. Each extraction has its advantages and disadvantages, but 
can all be used in forensic toxicology. This study focused on comparing LLE, SPE, and 
SLE. 
 
1.6.2 Liquid-Liquid Extraction 
 The principle behind LLE are the solubility of the components present 39. Two 
immiscible solvents are used, typically one aqueous and one organic. Once these solvents 
are added to the sample the analytes will travel into the solvent in which they are more 
soluble 1,39. The solvents chosen depend on the pKa, polarity, are the compounds acidic or 
basic to determine which solvents will be used to increase the solubility of the analytes into 
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one of the immiscible layers 1,39. Therefore, the different extractions can be acidic/neutral 
extractions or basic/neutral extractions. Depending on the method of analysis, the layer 
recovered can either be directly injected into the instrument, or dried down and 
reconstituted into a solvent that is more suitable for the instrument. 
LLE are carried out in one container in which all solvents and compound of interest 
are added, mixed, centrifuged, and the organic layer is removed. There is the potential to 
repeat these steps to increase the analyte recovery 8. A few advantages for LLE are that 
compared to dilute and shoot, phospholipid depletion, and protein precipitation the extracts 
are cleaner and can be more selective. However, these extractions require intensive manual 
labor, they are more difficult to automate, and a possibility for variability due to the 
differences in layer removal while pipetting 8. 
 
1.6.3 Solid Phase Extraction 
 When analytes of interest have similar polarities, or acid/base properties, LLE may 
not be suitable for their recovery. For these cases using SPE can be used 1,39. Solid phase 
extractions use adsorption of components onto a solid phase to separate unwanted 
components and extract analytes of interest 1,39. These extractions aid in removing 
interferences such as phospholipids found in blood, other interfering drugs, and other 
components found in the matrix, giving cleaner extracts. These packed columns consist of 
either silica or polymers 8. Sorbent beds composed of silica can only support a limited 
range of pH, the packing of the column is more variable, and the sorbent bed cannot dry 
while being conditioned and before the sample is loaded 1,8. Comparatively, sorbent beds 
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made of polymers can support a larger pH range, the packing is more homogenous, and 
there is a higher sample capacity 1,8. Solid phase extractions can be used for acidic, basic, 
or neutral compounds, in which the sorbent bed composition is adjusted to fit the type of 
analyte.  
The traditional steps for SPE methods begin with conditioning the column. This 
adjusts the pH of the sorbent bed and activates the functional groups in the sorbent bed. 
The next step is loading the sample, followed by washing to remove any matrix 
interferences or other interferences present. The final step is eluting the analytes of interest 
1,40. Some advantages of using a SPE method are that the extracts are clean, due to matrix 
interferences such as phospholipids being removed during the washing step and increased 
reproducibility 1,8. These methods can also be very selective, and there is the possibility for 
automation. Some disadvantages are that these processes can be time consuming with all 
the steps involved and there are costs involved due to buying the columns and ensuring all 
necessary equipment such as vacuums or positive pressure manifolds are purchased 8. 
 
1.6.4 Supported Liquid Extraction 
 Supported liquid extractions are a modified LLE. They use the same principles of 
combining water immiscible solvents to create analyte extraction 41,42. While a LLE method 
requires mixing the immiscible solvents by shaking, rocking, centrifuging, etc., SLE uses 
a stationary phase that captures the aqueous solution while the organic solvent flows 
through the stationary phase 41,42. The stationary phase is composed of diatomaceous earth 
which has a high silica content 1,8,42,43. Diatomaceous earth is composed of fossilized 
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diatoms that are high in silica content and found on the sea floor 42,44. Diatoms are closely 
related to algae and have a hard shell or skeleton composed of silica, resulting in 
diatomaceous earth containing a rich silica content 42,44. The diatomaceous earth is ground 
resulting in large, irregular shaped particles with high surface area leading to greater 
absorption increasing the extraction efficiency 1,8,42.  
 The three steps involved in the SLE process are, loading the column, waiting while 
the matrix is absorbed into the column, and eluting the analytes of interest 8,41,42. Some 
advantages of SLE methods are their reproducibility, increased analyte recovery, and 
decreased ion suppression. These methods give cleaner extracts compared to LLE methods 
due to phospholipids and other matrix interferences binding to the column and not eluting 
out. Supported liquid extractions can be more selective than LLE methods. Since there are 
no washing steps the eluent is not as clean as SPE samples and the selectivity is less than 
that of SPE methods, however the amount of time consumed is reduced compared to both 
LLE and SPE 8. Like SPE, automation is possible as well. Analysis is capable for acidic, 
basic, or neutral compounds and for all matrices. 
 
1.7 Research Objectives 
THC and synthetic cannabinoids are commonly encountered drugs in forensic 
toxicology cases, therefore, being able to extract these compounds and their metabolites is 
important. With a variety of sample preparation techniques available on the market 
determining the differences would be beneficial for choosing the most effective and 
efficient method. 
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The primary purpose of this study was to develop and validate three different 
sample preparation techniques for the analysis of THC, 11-hydroxy-THC, THCCOOH, 
AB-FUBINACA, AB-FUBINACA metabolite 3, and AB-PINACA. The three different 
sample preparation techniques consisted of LLE, SPE, and SLE methods. Analysis and 
quantitation were completed using liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Each method was validated to quantitate each of the six compounds of interest 
using the same linear dynamic range for each method. Additionally, the study looked at the 
ability to use the same sample preparation method on both human urine and whole blood. 
Validation parameters were assessed using American Standards Board (ASB) Standard 
036, Standard Practices for Method Validation in Forensic Toxicology 45. Following 
validation, the results of the three sample preparation techniques were then compared 
against each other, along with comparing other parameters such as the number of resources 
used and the amount of time consumed by each method. 
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2. MATERIALS AND METHODS 
2.1 Instrumentation Theory 
2.1.1 Liquid Chromatography 
 Liquid chromatography (LC) uses liquid to separate compounds and analytes of 
interest within a sample. Chemical principles of compounds are used for this separation. A 
system consists of two mobile phases that are controlled by pumps that cause the mobile 
phases to flow through the system where they are degassed to remove any bubbles and 
mixed together 1,46. The mobile phases may be used either as isocratic flow which consists 
of a consistent ratio of mobile phase A to mobile phase B, or gradient flow where the ratio 
of mobile phase A to mobile phase B changes over time 1. An autosampler houses the 
sample until it is injected into the mobile phase which then travels into the stationary phase, 
or column which is housed in an oven 46. A common system is a reverse phase system in 
which the mobile phases are more polar than the stationary phase 1. While in the column 
the compounds are separated based on their affinity, adsorption, ion exchange, and size 
exclusion for the stationary phase or the mobile phase. As the compounds elute from the 
column they then travel to the detector, in which a chromatogram is produced 46. The 
chromatogram plots the response as a function of the retention time, or the amount of time 
from injection to the compound reaching the detector 46. A variety of detectors are available 
for further analysis, such as ultraviolet-visible spectroscopy, infrared spectroscopy, and 
mass spectrometry 1,46. 
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2.1.2 Mass Spectrometry 
 Mass spectrometry (MS) is a technique used for the detection of ions present in a 
sample. Determining the molecule(s) present is based on the fragmentation and ionization 
patterns of molecules while they are in the gas phase 39,47. Molecules fragment in specific 
patterns that are distinctive to that molecule, allowing for elucidation of the different 
molecules present. 
 Mass spectrometers are composed of five components, the ion source, mass 
analyzer, ion detector, data system and a vacuum. There are multiple types of ion sources, 
including, electron ionization, chemical ionization atmospheric pressure chemical 
ionization, and electrospray ionization (ESI). The ion source is responsible for the 
ionization of molecules once introduced into the system 47. ESI, which is commonly 
coupled with LC-MS systems, uses atmospheric pressure and composed of a capillary tube 
and a counter electrode 39,47, which is heated to high temperatures.  The capillary tube and 
counter electrode have a potential difference in which an electric current is created resulting 
in charge accumulation on the surface of the liquid as it emerges from the capillary tube 
39,47. Droplets are multiplied further and further as solvent evaporates and the electric 
charge increases on the surface causing the droplets to split 39,47. The process repeats until 
the ions are ejected from the droplet. A nebulizing gas, typically nitrogen, can be used to 
assist in the formation of these droplets, along with maintaining a constant spray 47. The 
ions then pass through a sampling cone and are focused as they pass through vacuums and 
make their way to the analyzer 39. 
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 Ions leaving the source are accelerated through the mass analyzer and focused using 
an electric field and finally separated by their mass to charge ratio (m/z) 47. Quadrupole 
mass analyzers are a commonly employed type of mass analyzer which consist of four 
parallel rods centered around a central axis 47. Radiofrequency and direct current are 
applied to the rods 47. As ions travel through the quadrupoles, only ions with a specific m/z 
for certain radiofrequency and direct current potentials will successfully reach the detector 
1,39,47. Once the ions travel through the mass analyzer and reach the ion detector the relative 
intensity of each m/z is recorded creating a mass spectrum unique to that molecule 47. The 
data system then plots the relative intensity versus the m/z to give a visual representation 
of the mass spectrum. Both the mass analyzer and ion detector are under vacuum when 
using ESI. 
 
2.1.2.1 Tandem Mass Spectrometry 
 Tandem mass spectrometry (MS/MS) is a type of mass analyzer that consists of 
multiple quadrupoles, most commonly used is a triple quadrupole, consisting of three 
quadrupole sets. The precursor ion is detected in the first quadrupole 47. As the precursor 
ions move into the second quadrupole the ions are fragmented into product ions due to 
radiofrequency only being applied to the rods, creating a collision cell 39,47. The third 
quadrupole is used as a mass analyzer like the first quadrupole and the m/z of the product 
ions are detected here 47. The system names these different quadrupoles as Q1, where the 
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precursor ion is detected, Q2 where collision energy is applied fragmenting the precursor 
ion, and Q3 where the product ions are detected 47. 
 
2.2 Reagents and Instrumentation 
2.2.1 Standards/Reagents 
Certified reference standards of D9-THC, (±)-11-hydroxy-D9-THC, (±)-11-nor-9-
carboxy-D9-THC, AB-FUBINACA, AB-FUBINACA metabolite 3, and AB-PINACA, all 
with a concentration of 1 mg/mL, were purchased from Cayman Chemical (Ann Arbor, 
MI, USA). D9-THC-d3, (±)-11-hydroxy-D9-THC-d3, and (-)-11-nor-9-carboxy-D9-THC-
d3, all at a concentration of 100 µg/mL, AB-FUBINACA-d4, and AB-PINACA-d9, both 
with a concentration of 1 mg/mL, were used as certified reference internal standards, and 
were all purchased from Cayman Chemical.  
Mobile phase and needle wash consisted of reagent grade Formic Acid, ³ 95%, 
(Sigma-Aldrich, St. Louis, MO, USA), Optima® LC/MS Acetonitrile (ACN), Optima® 
LC/MS Methanol (Fisher Chemical, Fair Lawn, NJ, USA), and ultrapure deionized water 
(DI water) prepared using a Millipore Milli-Q Ultrapure (Type 1) water system (Millipore 
Sigma, Burlington, MA, USA).  
For the extraction protocols HPLC Grade Hexanes, Optima® Ethyl Acetate, 
Certified ACS Plus Ammonium hydroxide (NH4OH) (Fisher Chemical, Fair Lawn, NJ, 
USA), HPLC grade, 99+% Methyl tert-butyl ether (MTBE) (Alfa Aesar, Ward Hill, MA, 
USA), reagent ACS grade Glacial Acetic Acid (Acros, New Jersey, USA), DI water and 
ACN were used. 
19 
2.2.2 Specimen 
 Human urine was donated following approved institutional review board (IRB) 
guidelines (Boston University School of Medicine, Boston, MA, USA). Human whole 
blood was purchased from Equitech Enterprises (Kerrville, TX, USA), Biological 
Specialty Corporation (Colmar, PA, USA), and Boston Medical Center Blood Bank 
(Boston, MA, USA).  
 
2.2.3 LC-MS/MS Instrumentation 
 Analysis was conducted on a Shimadzu Prominence Ultra-Fast Liquid 
Chromatograph consisting of a DGU-20A5R Degassing Unit, two LC-20AD pumps, one 
for each mobile phase, SIL-20AC HT Autosampler, CTO-20A column oven, and a CBM-
20A communication bus module (Shimadzu, Kyoto, Japan). A 4000 Q Trap Tandem Mass 
Spectrometer (LC-MS/MS, SCIEX, Framingham, MA, USA), equipped with ESI as the 
detector. The chromatography was carried out on a XBridgeâ C18 3.5 µm, 2.1 x 50 mm 
column (Waters Corporation, Milford, MA, USA) or a Kinetexâ 2.6 µm C18 100 Å, 50 x 
2.1 mm column (Phenomenex, Torrance, CA, USA). Data collection was completed on 
Analyst® (version 1.6.2) software (SCIEX) and MultiQuant® (version 3.0.5373.0) 
software (SCIEX) was used for all data analysis. Statistical analysis was performed on 






2.3.1 LC-MS/MS Parameters 
The following parameters are for LC-MS/MS analysis on the SCIEX instrument. A 
XBridgeâ C18 3.5 µm, 2.1 x 50 mm column was used for LLE and SPE method analysis 
and a Kinetexâ 2.6 µm C18 100 Å, 50 x 2.1 mm column was used for SLE method 
analysis. The flow rate was 0.8 mL/min with an injection volume of 10 µL. Mobile phase 
A was 0.1% formic acid in DI Water and mobile phase B was 0.1% formic acid in ACN. 
All mobile phases were prepared in the laboratory. A gradient flow was used beginning 
with 30% mobile phase B, ramping up to 90% mobile phase B and finishing back at 30% 
mobile phase B (Table 1, Figure 2). The total run time was 9 min with a needle rinse before 
and after each aspiration. Each needle rinsed was 1,000 µL of needle wash solution 
(40:40:20 ACN:methanol:DI water) which was prepared in the laboratory. The rinse time 
was 5 seconds (sec) with a rinsing speed of 35 µL/sec. The sampling speed was 
programmed to 3.0 µL/sec. The autosampler was set to 15°C and the column oven was set 
at 40°C. 
 
Table 1. Mobile phase conditions. 
Gradient 
Time (min) % Mobile Phase A % Mobile Phase B 
0.01 70 30 
0.5 70 30 
5 10 90 
8.5 10 90 




Figure 2. Gradient Curve for Mobile Phase B.  
 
Each analyte of interest was monitored using to ion transitions, the quantitative 
(quant) and qualitative (qual) ions. The quant ion was used for all the quantitative 
calculations and studies. The qual ion was monitored to ensure the analyte’s presence. 
Determining the ratio between the quant and qual ions for an analyte and monitoring the 
ion ratio during analysis ensures the compounds presence and not another compound with 
similar fragmentation. The internal standards were monitored using one transition. Table 2 
shows the precursor ion (Q1 Mass) along with the quant and qual product ions (Q3 Mass) 
for each analyte and internal standard. The declustering potential (DP), collision energy 







Table 2. Parent compound and transition ions. The precursor mass, quant and qual 
ion transition masses, and DP. 







D9-THC 315.3 193.4 123.3 90.0 
11-hydroxy-D9-THC 331.3 193.1 313.4 64.0 
11-nor-9-carboxy-D9-
THC 
345.2 299.4 327.3 81.0 
AB-FUBINACA 369.1 253.2 324.5 63.0 
AB-PINACA 331.3 215.3 314.4 81.0 
AB-FUBINACA 
metabolite 3 
370.2 109.2 253.1 72.0 
D9-THC-d3 318.3 196.2 - 84.0 
11-hydroxy-D9-THC-d3 334.3 316.4 - 73.0 
11-nor-9-carboxy-D9-
THC-d3 
348.2 330.3 - 86.0 
AB-FUBINACA-d4 373.1 328.3 - 66.0 
AB-PINACA-d9 340.3 224.2 - 66.0 
 
2.3.2 Sample Preparation 
2.3.2.1 Standard Solutions and Quality Controls 
 The certified reference standards, stored at approximately -20°C, were used to 
create working stock solutions containing all six compounds of interest. The certified 
reference standards were diluted with methanol to create the spiking mixes to prepare the 
calibrators, quality control (QC), LOD and LOQ samples (Table 3). Certified reference 
standards of the deuterated internal standards were diluted in methanol for a working 
solution of 250 ng/mL. For all experiments, 400 µL of blood or urine was used. For double 
blank samples no internal standard or calibrator/control was added, thus giving a base line 
for a clean sample. Blank samples were prepared by adding internal standard only. 
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Table 3. Preparation of calibration curve, QCs, LOD and LOQ in blood and urine. 
The final concentration for the calibration curve and QCs starting with the working 





Total Vol (µL) in 
blood/urine 
Final Conc. 
(ng/mL) Labeled As 
Calibrators in Blood/Urine 
10 40 400 1 Cal1 
25 40 400 2.5 Cal2 
50 40 400 5 Cal3 
100 40 400 10 Cal4 
200 40 400 20 Cal5 
300 40 400 30 Cal6 
500 40 400 50 Cal7 
QCs in Blood/Urine 
30 40 400 3 LQC 
150 40 400 15 MQC 
400 40 400 40 HQC 
LODs and LOQs in Blood/Urine 
0.1 40 400 0.01 LOD1 
1 40 400 0.1 LOD2 
2.5 40 400 0.25 LOD3 
5 40 400 0.5 LOD4 
7.5 40 400 0.75 LOD5 
10 40 400 1 LOQ1 
INTERNAL STANDARD 
250 40 400 25 ISTD 
 
 
2.3.2.2 Liquid-Liquid Extraction Method 
 Extractions were carried out in 7 mL clear glass vials with PTFE lined screw tops 
(Supelco, Bellefonte, PA, USA). The urine or blood (400 µL), spiking solution (40 µL), 
and internal standard (40 µL) were added to the vials, along with 750 µL DI water, 200 µL 
20% glacial acetic acid, and 4 mL of hexane:ethyl acetate:MTBE (80:10:10). The glacial 
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acetic acid and organic solution were prepared in the laboratory. The vials were rocked for 
30 min followed by 10 min in the centrifuge at 3500 rotations per minute (rpm) then placed 
in a freezer at approximately -20°C for around 2 hours. The organic layer was transferred 
to 15 mL glass test tubes and evaporated to dryness on the nitrogen evaporator at 40°C for 
approximately 20 min (Organomation Berlin, MA, USA). The samples were reconstituted 
in 100 µL of 0.1% formic acid in DI water:0.1% formic acid in ACN (70:30) and 
transferred into LC vials with inserts and placed in the LC-MS/MS autosampler for 
analysis. 
  
2.3.2.3 Solid Phase Extraction Method 
For each extraction, 400 µL of urine or blood was transferred into a 6 mL glass test 
tube, with 40 µL of the internal standard and 40 µL of the appropriate spiking solution. 
The following sample pretreatment and the extraction parameters were modified from the 
UCT Application Note for the Styre ScreenÒ THC 6 mL Tube 48. To the test tube, 1 mL 
of ice cold ACN was added. The samples were vortexed, then centrifuged at 4,000 rpm for 
10 min. The liquid was reduced down to 100 – 200 µL on an evaporator with nitrogen air 
flow and then 1 mL of DI water was added. 
UCT Styre ScreenÒ THC 3 mL 60 mg columns (United Chemical, Bristol, PA, 
USA) were used for the extraction. The columns were loaded onto a UCT positive pressure 
manifold. The matrix was then loaded onto the columns and absorbed into the column bed 
using positive pressure flow of 1 mL/min. The loaded column was washed with 1 mL of 
DI water:ACN:NH4OH (84:15:1), made daily, with a positive pressure of 1 mL/min 
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followed by 11 min of pressure for drying. Clean test tubes were then placed under the 
columns for collection and 1.5 mL of hexane:ethyl acetate:glacial acetic acid (49:49:2) was 
added to the columns to elute the compounds of interest. Positive pressure with a flow rate 
of 1 mL/min was applied. The samples were then dried on an evaporator with nitrogen flow 
at 40°C for approximately 15 min and reconstituted in 100 µL of 0.1% formic acid in DI 
water:0.1% formic acid in ACN (70:30). The final solution was transferred to LC vials 
with inserts and placed in the LC-MS/MS autosampler tray. 
 
2.3.2.4 Supported Liquid Extraction Method 
Into 6 mL glass test tubes, 400 µL of urine or blood was added along with 40 µL 
of the internal standard and 40 µL of appropriate spiking solution. To this, 200 µL of 5% 
glacial acetic acid was added to each test tube and then vortexed. For the blood samples, 
after vortexing the sample were centrifuged for 5 mins at 4000 rpm. The supernatant was 
transferred onto Biotage IsoluteÒ SLE+ 1 mL columns (Biotage, Charlotte, NC, USA) 
with 15 mL glass test tubes below to collect all liquid. After applying a quick pulse of 
pressure, the sample was absorbed onto the columns for five minutes using gravity flow. 
Following absorption, 3 mL of hexane:ethyl acetate:MTBE (80:10:10) was applied and 
allowed to flow for 5 minutes by gravity. This was repeated one more time. The extraction 
product was placed on a nitrogen evaporator and dried at 40°C for approximately 20 min. 
Following drying, 100 µL of 0.1% formic acid in DI water:0.1% formic acid in ACN 
reconstitution solution was added and the samples were then transferred to LC vials with 
inserts and placed in the LC-MS/MS autosampler tray. 
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2.3.3 Method Validation 
 Method validation was completed following the ASB Method Validation 
parameters 45. These included calibration model, bias and precision, LOD, LOQ, analyte 
recovery, carryover, interferences, ion suppression and enhancement, dilution integrity, 
and processed stability 45. Chromatography analysis was completed using MultiquantÒ 
software and statistical analysis was performed using Microsoft Excel. 
 Other parameters of interest for the comparison of the various sample preparation 
techniques were the amount of time each technique took, the number of reagents, the 
amount of reagent and the resources consumed. 
 
2.3.3.1 Calibration Model 
 Calibration model was carried out over a series of five different prepared calibration 
curves for each of the six analytes of interest. Each curve was prepared separately, along 
with the three QCs prepared in triplicate by spiking negative blood or urine. Under ASB 
guidelines, the calibration curve must be validated with a minimum of six non-zero 
concentrations 45. Seven points were used for this project, 1 ng/mL, 2.5 ng/mL, 5 ng/mL, 
10 ng/mL, 20 ng/mL, 30 ng/mL, and 50 ng/mL. The three QCs fell between all 7 points, 
with a low QC of 3 ng/mL, a middle QC of 15 ng/mL, and a high QC of 40 ng/mL. The 
best fit curve was determined for each compound and the coefficient of correlation (r2) 
value was recorded for each calibration curve. A residual plot was created for each analyte 
of interest over the calibration range to show whether the range was linear or quadratic. 
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The qual/quant ion ratio was also monitored and all values needed to fall within ± 20% of 
this average value. This ratio was monitored for all validation parameters. 
 
2.3.3.2 Bias 
 Bias studies were performed to determine the accuracy of the sample preparation 
technique for each analyte of interest. Bias studies were performed for each compound 
preparing the three QCs (3 ng/mL, 15 ng/mL, 40 ng/mL) in triplicate over five different 
runs. Bias was determined using the following equation and each value for each 
concentration needed to fall within ± 20% 45.  
Bias (%)= 
Calculated Average-Actual Average
Nominal Average *100 
These samples were prepared along with the calibration model samples and were also used 
for the precision studies. 
 
2.3.3.3 Precision 
 Precision studies were performed to determine the reproducibility and repeatability 
for each sample preparation technique for each of the six analytes of interest. These values 
represent an analyst’s ability to repeat these experiments from day to day and reproduce 
the same values. Precision studies were carried out using the same QC samples prepared 
in triplicate as the bias studies and carried out along with calibration model. Precision was 
recorded as the % coefficient of variation (% CV) and needed to fall within ± 20% for the 
method to be validated.  
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Two forms of precision were calculated for each analyte, within-run precision and 
between-run precision. Within-run precision assesses the repeatability of the results during 
the same run. A within-run precision value was determined for each QC value for each 
individual run using the standard deviation and average calculated concentration.  
Within-run Precision (% CV)= 
Standard Deviation
Average Calculated Concentration *100 
The overall within-run precision was calculated by averaging every within-run value. 
Using the 15 samples from all five runs for each concentration, the between-run 
precision was determined. The between-run precision represents how close together the 
calculated concentration values were over all five runs. This value assesses the ability to 
repeat the experiment from day to day and be able to reproduce the results. The overall 
between-run precision was then determined by averaging the three QC between-run values. 
Between-run Precision (% CV)= 
Standard Deviation of all samples 
Grand Average Calculated Concentration *100 
 Finally, the grand between-run precision was determined by taking the standard 
deviation of every QC sample over all five runs at all concentrations divided by the average 
accuracy for all 45 samples and multiplying this value by 100 to create a percentage. 
 
2.3.3.4 Recovery 
 For analyte recovery, 10 different matrix lots were used in which two different 
concentrations were monitored, a low (10 ng/mL) and a high (30 ng/mL). Samples for all 
10 matrix lots were prepared in duplicate and spiked with analyte and internal standard 
pre-extraction. Another set of all 10 matrix lots were prepared in duplicate and spiked with 
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Post Extraction Area *100 
The area was monitored for this validation parameter; therefore, all low concentration 
samples were run on the same day and all high concentration samples were run on the same 
day. 
 
2.3.3.5 Limit of Detection and Limit of Quantitation 
 For LOD, three different matrix lots were used, with each concentration of interest 
prepared in duplicate. Analysis was carried out over three runs using the established 
calibration model. The final concentrations consisted of 0.01 ng/mL, 0.1 ng/mL, 0.25 
ng/mL, 0.5 ng/mL, 0.75 ng/mL, and 1 ng/mL. A double blank was also prepared in 
duplicate for each matrix lot. For each double blank, the signal area at the analyte of 
interest’s retention time was manually integrated using MultiQuantÒ. This area was then 
averaged and a standard deviation was determined. The LOD was determined if the average 
signal area for a concentration was greater than the average double blank area plus 3.3 
times the standard deviation, along with the qual/quant ion ratio within ± 20% of the 
average qual/quant ion ratio and Gaussian peak shapes. 
 Limit of quantitation was determined using three different matrix lots prepared in 
duplicate, over three runs. A series of concentrations at or below the lowest calibrator were 
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run and the calculated concentration % CV needed to fall within ± 20% for the value to be 
considered as a limit of quantitation. 
 
2.3.3.6 Ion Suppression or Enhancement 
 Ion suppression and enhancement were determined by preparing 10 different lots 
of matrix in duplicate and spiking with analyte and internal standard post extraction. A neat 
solution was also prepared and injected six times. Suppression or enhancement was 
calculated with the following equation: 
% Ion Suppression or Enhancement= *	
Average Post Area
Average Neat Area -1, *100 
Like analyte recovery, the peak area is of interest for this study instead of concentration. 
Analyte recovery and ion suppression or enhancement was carried out at the same time 
using the same post spiked samples. 
 
2.3.3.7 Carryover, Interferences, Dilution Integrity, Stability 
 Carryover was determined by running double blanks directly after the highest 
calibrator and the peak area was determined. The average peak area needed to be less than 
10% of the lowest calibrators peak area for there to be considered no carryover. 
 When looking at different interferences during analysis one source of potential 
interferences studied were different drugs and drug classes. These drugs may mask the 
analyte being analyzed. They may also enhance or suppress the signal therefore when using 
the method for quantitative purposes the calculated concentration may be greater than or 
less than the actual concentration. Common interferences were looked at by running 
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commonly encountered drugs (Table 11) through the extraction method, LC-MS/MS 
method, and quantitation method to ensure no interferences occurred. The drugs were 
prepared in three different drug mix groups, with a final concentration of 200 ng/mL once 
spiked in the matrix of interest (Table 11). Interference from the internal standard was 
studied by looking at negative matrix sources with only internal standard added and 
assessing peak area at the analyte retention time to. Blank sources of matrix were fortified 
with the highest calibrator only and the signal area was assessed at the internal standard 
retention to assess any interference with the internal standards. All area less than 10% of 
the lowest calibrator was considered as no interference.  
 Matrix interferences were analyzed by running 10 separate lots of matrix in double 
blank form and analyzing the signal area at the retention time of the analyte of interest. If 
the area was less than 10% that of the lowest calibrator there was considered no matrix 
interference. 
 Dilution integrity was studied to ensure that if an unknown sample had a 
concentration higher than the highest calibration point, the sample could be diluted and 
give an accurate result. This was completed by looking at a 1:10 and a 1:50 dilution. Each 
dilution was prepared in triplicate and run over five runs. Within-run precision, between-
run precision, and bias were calculated to determine the integrity of diluting the samples. 
 To ensure a sample could be kept on the autosampler for more than one day due to 
atypical events processed sample stability was studied. Processed stability looked at the 
length of which a sample could sit after being processed before the results were no longer 
acceptable. The study was carried out over 72 hrs. The QCs were prepared in triplicate and 
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injected at 0 hr, 24 hr, 48 hr, and 72 hr. The ion ratio of quant ion:internal standard ion was 




3.1 Analyte Detection 
For the MS parameters, the signal intensity was greater for the synthetic 
cannabinoids compared to the THC compounds, therefore, method development was more 
focused on the optimization of the THC compounds. 
Initial analysis for determining the best column and LC parameters was completed 
using neat solutions, which consisted of the calibration or QC standards with internal 
standard prepared in mobile phase. A C18 and F5 (Phenomenex, KinetexÒ 2.6 µm F5 100 
Å, 50 x 3.0 mm) column were initially assessed for their use, with the C18 column being 
determined as the best column for analysis, due to the F5 column creating peaks with more 
tailing and less resolution of 11-hydroxy-THC and THCCOOH.  
The retention times were determined using the earlier mentioned LC parameters 
(Table 4). Two different analytical columns with the same length and diameter, were used 
for validation analysis, a XBridgeÒ C18 and a KinetexÒ C18. Figure 3 shows the retention 








Table 4. Retention time of analytes of interest. The retention times of the six analytes 






AB-FUBINACA 2.09 2.33 
AB-PINACA 2.46 2.64 
AB-FUBINACA metabolite 3 2.52 2.73 
11-hydroxy-THC 3.39 3.50 
THCCOOH 3.49 3.56 
THC 4.51 4.61 
 
  
Figure 3. Liquid chromatogram for the XBridgeÒ C18 column in a neat solution. All 
six compounds are resolved. (a) AB-FUBINACA, (b) AB-PINACA, (c) AB-FUBINACA 
metabolite 3, (d) 11-hydroxy-THC, (e) THCCOOH, (f) THC. 
 
3.2 Urine Analysis 
3.2.1 Calibration Range 
The concentration range of interest for the calibration curves was determined from 
studies and commonly reported values of these compounds in the human body. With newer 
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synthetic cannabinoids and novel psychoactive substances having stronger effects with 
lower dosage the initial goal for the lower end of the calibration range was 0.01 ng/mL. 
Preliminary trial assessment revealed detection and quantitation of levels below 1 ng/mL 
would not be reproducible for the analytes of interest. Detection for the THC compounds 
was not possible at a concentration of 0.01 ng/mL either. To ensure repeatability and 
reproducibility, the lower end of the calibration curve was then set at 1 ng/mL, while the 
upper end was set to 50 ng/mL. The upper limit of the linear dynamic range was set above 
typically recorded levels of detection for the analytes of interest. To ensure the range of 1 
ng/mL to 50 ng/mL was linear, five calibration curves were analyzed. The r2 value was 
determined. This value needed to be 0.99 or greater for the curve to be accepted. A residuals 
plot for each of the five curves was also created to show the linearity of the range. One 
such plot can be seen below in Figure 4.  
The r2 values and residue plots were created for all six compounds being studied 
for each sample preparation technique. The r2 values for each compound of interest are 
recorded in Table 5. For each analyte the r2 value is compared to one another for each of 
the three sample preparation techniques. THC had the best r2 value of 0.999 with the LLE 
and SPE method. 11-hydroxy-THC and THCCOOH had the best r2 value of 0.999 for the 
SLE method. Looking at the synthetic cannabinoids, the LLE method had the best r2 value, 
with 0.999 for AB-FUBINACA, 0.998 for AB-FUBINACA met 3 and AB-PINACA, while 
the SPE and SLE methods had values between 0.995 and 0.997 for the synthetic 
cannabinoids. All of these values are acceptable under the ASB guidelines and all three 




Figure 4. Residuals plot for THCCOOH using the LLE sample preparation technique 
for urine. This residuals plot shows random spacing around the zero value at the six 
calibration points expected of a linear range. 
 
The residual plot looks at all seven calibration points. For each run the calculated 
concentration is subtracted from the actual concentration to give a residual value. These 
values are then summed together in which the sum must equal zero. If the curve is linear 
the residuals plot values will be spaced relatively evenly around zero and look scattered, 
while a quadratic curve will form a U-shaped plot 45. The residual plots give another visual 
representation of the shape of the curve being analyzed, and assist the analyst in 
determining the linear dynamic range for the analytes of interest. For each method, the 
linear dynamic range of 1 ng/mL to 50 ng/mL was appropriate according to the residues 
plot. For all three sample preparation methods, AB-FUBINACA, AB-FUBINACA 
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metabolite 3, and AB-PINACA residuals plots were beginning to resemble that of quadric 
curves with the linear dynamic range extending to 50 ng/mL (Figure 5). The r2 values were 
still greater than 0.995, therefore the linear dynamic range was still acceptable, however, 
for future studies, using a range that ends of 40 ng/mL would be appropriate for synthetic 
cannabinoids. This value is also on the high end of levels detected in case samples. 
 
 
Figure 5. Residuals plot of AB-PINACA using the SLE method for urine. A U-shape 
is beginning to form over the concentration range of 1 ng/mL to 50 ng/mL, representing a 







Table 5. r2 values for urine. A comparative look at the r2 
values for the LLE, SPE, and SLE sample preparation methods. 
 r2 values 
Compound Name LLE SPE SLE 
THC 0.999 0.999 0.998 
11-hydroxy-THC 0.999 0.999 0.999 
THCCOOH 0.999 0.999 0.999 
AB-FUBINACA 0.999 0.997 0.997 
AB-FUBINACA met 3 0.998 0.995 0.995 
AB-PINACA 0.998 0.996 0.996 
 
3.2.2 Bias and Precision 
The three QCs, 3 ng/mL, 15 ng/mL, and 40 ng/mL were prepared in triplicate for 
five separate runs. These samples were used to calculate the bias and precision for each of 
the six analytes of interest for all three sample preparation techniques. The LLE method 
had the largest bias and poorest accuracy for all compounds except for AB-PINACA, 
which had as similar value as the SLE method (Table 6). For THC, its two metabolites and 
AB-FUBINACA metabolite 3, the SLE method had the best overall bias with THC, 11-
hydroxy-THC, and AB-FUBINACA metabolite 3 having values under 2%, while 
THCCOOH had a value close to 3%. AB-FUBINACA and AB-PINACA had the best bias 
values for the SPE method with AB-PINACA having the best bias value compared to all 
compounds and all sample preparation techniques.  
 For the synthetic cannabinoids, the LLE had the greatest between-run precision, 
comparatively, THC and its two metabolites had the greatest between-run precision for the 
SPE method. The SLE method had the worst between-run precision for THC, 11-hydroxy-
THC, AB-FUBINACA, and AB-PINACA, while the best between-run precision for AB-
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FUBINACA metabolite 3 was using the SLE method. Both the LLE and SPE had similar 
between-run values for all compounds.  
Looking at the within-run precision THC, 11-hydroxy-THC, and AB-FUBINACA 
had the best values for the SPE method. The LLE method had the best within-run precision 
for THCCOOH, while AB-FUBINACA metabolite 3 and AB-PINACA had the greatest 
within-run precision for the SLE method. All bias and precision values fell well within the 
accepted ASB guidelines of ± 20%, with all values falling within ± 10%. With all these 
values falling within ± 10% the LLE, SPE, and SLE are sound methods to be used for 
forensic toxicology analysis. 












Name LLE SPE SLE LLE SPE SLE LLE SPE SLE 
THC -9.62 -2.42 -1.16 4.28 3.88 9.32 2.55 2.21 5.69 
11-hydroxy-
THC 
-7.62 -2.28 -1.51 5.10 4.71 6.37 3.20 2.86 2.93 
THCCOOH -8.52 -3.07 -3.02 4.89 3.72 4.66 1.81 2.50 3.01 
AB-FUBINACA -6.06 -1.05 -3.11 3.66 3.87 4.81 2.04 1.68 2.21 
AB-FUBINACA 
met 3 
-6.39 -2.25 -1.64 5.90 6.47 5.55 3.06 4.10 2.36 
AB-PINACA -2.60 -0.61 -2.68 6.53 6.75 7.08 4.10 5.04 4.01 
 
3.2.3 Analyte Recovery 
 Recovery analysis was completed for each analyte over all three sample preparation 
techniques. A low concentration of 10 ng/mL and a high concentration of 30 ng/mL were 
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assessed for this study (Table 7) using10 different lots of urine. The analyte with the lowest 
recovery was THC, with a recovery of around 25% for both the SPE and SLE methods, 
while the LLE method had a recovery around 45%. This low level of recovery is especially 
interesting for the SPE method because the SPE columns used were designed specifically 
for the extraction of THC. The transfer of the sample from different test tubes and vials 
during each method could result in a lower recovery for THC due to compound adhering 
to glass and not all sample being transferred to the next test tube. For the 11-hydroxy-THC 
and all the synthetic cannabinoids, the LLE method had a recovery of greater than 100%, 
with AB-FUBINACA having the greatest recovery average of 114.16%, while THCCOOH 
had a recovery averaging 99.72%. Compared to the SPE and SLE methods, the lower 
concentration studied had a greater recovery for all compounds, while the higher 
concentration had greater recovery for the SLE method. All analytes except THC had a 
higher recovery for the higher concentration studied for the SPE method. For all analytes, 
the SPE method had the lowest recovery, with each analyte other than THC having a 
recovery around 10 – 15% less than the SLE method. The synthetic cannabinoids had a 
recovery ranging from 76.68 – 82.06% when using the SLE method, while 11-hydroxy-
THC and THCCOOH had a recovery ranging from 55.92 – 65.94% using the SLE method. 
The analyte with the greatest recovery for the LLE method was AB-FUBINACA, while 
the SPE and SLE analyte with the greatest recovery was AB-PINACA. 
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Table 7. Analyte recovery for urine. Two concentrations were assessed, 10 ng/mL and 
30 ng/mL. Both are shown below along with a comparison of all three sample methods 
for each analyte. 
 Recovery for 10 ng/mL (%) Recovery for 30 ng/mL (%) 
Compound Name LLE SPE SLE LLE SPE SLE 
THC 52.21 25.5 25.98 43.47 21.24 28.64 
11-hydroxy-THC 109.86 47.2 60.82 98.74 49.16 65.94 
THCCOOH 107.46 44.68 55.92 91.98 45.82 61.36 
AB-FUBINACA 119.43 61.08 76.68 108.89 61.72 81.80 
AB-FUBINACA met 3 118.04 50.47 79.20 106.78 54.65 79.32 
AB-PINACA 111.35 62.97 79.52 105.43 66.64 82.06 
 
3.2.4 Limit of Detection and Limit of Quantitation 
The limit of detection was less than 1 ng/mL for most of the compounds for all 
three sample preparation techniques (Table 8). AB-FUBINACA had consistent LOD (0.01 
ng/mL) between the different sample preparation methods. Concentration values were the 
same between the LLE and SPE techniques for THCCOOH and AB-FUBINACA 
metabolite 3, 0.25 ng/mL and 0.1 ng/mL respectively, while AB-PINACA had the same 
value, 0.1 ng/mL, for the SPE and SLE techniques. THC had a lower LOD (0.25 ng/mL) 
using the LLE sample preparation technique while 11-hydroxy-THC had a lower LOD 
(0.25 ng/mL) for the SLE. The SPE method had the highest LOD for THC and 11-hydroxy-
THC with a value of 1 ng/mL.  
AB-FUBINACA was the only analyte that was able to reach the initial goal of 0.01 
ng/mL for a level of detection for each of the three sample preparation techniques. AB-
PINACA was able to reach 0.01 ng/mL for the LLE method, while AB-FUBINACA 
metabolite 3 was able to reach 0.01 ng/mL of the SLE method. THCCOOH had the lowest 
LOD, reaching 0.1 ng/mL for the SLE method, and 0.25 ng/mL for the LLE and SPE 
42 
method. The lowest concentration able to be detected for both THC and the first metabolite 
of THC, 11-hydroxy-THC, was 0.25 ng/mL. The SLE method had the lowest LOD for 
THCCOOH, 11-hydroxy-THC and AB-FUBINACA metabolite 3. The LLE method had 
the lowest LOD for THC and AB-PINACA.  
Table 8. Limit of detection for urine. A comparative look at the LLE, SPE, and SLE 
sample preparation techniques for the limit of detection. 
 LOD values (ng/mL) 
Compound Name LLE SPE SLE 
THC 0.25 1 0.5 
11-hydroxy-THC 0.5 1 0.25 
THCCOOH 0.25 0.25 0.1 
AB-FUBINACA 0.01 0.01 0.01 
AB-FUBINACA met 3 0.1 0.1 0.01 
AB-PINACA 0.01 0.1 0.1 
 
When analyzing the LOQ for each compound a %CV of ± 20% for the calculated 
concentration was needed to state a LOQ value for that compound. The lowest LOQ for 
each compound was determined to be 1 ng/mL for the LLE and SPE sample preparation 
methods. A lower LOQ was determined for each analyte using the SLE method (Table 9). 
AB-PINACA was the exception in that the lowest LOQ of 1 ng/mL was the same for all 
three sample preparation techniques. For the SLE method, 11-hydroxy-THC and 
THCCOOH had the lowest LOQ of all compounds at 0.5 ng/mL. THC, AB-FUBINACA 
and AB-FUBINACA met 3 had an LOQ of 0.75 ng/mL for the SLE method. For AB-
FUBINACA and AB-PINACA, values such as 0.25 ng/mL and 0.5 ng/mL could sometimes 
be accurately calculated using the calibration curve for the run, however the % CV was 
always greater than the allowed 20%. Therefore, these values could not be determined as 
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the lower LOQ for the LLE, SPE, and SLE sample preparation techniques, even though 
the LOD was 0.01 ng/mL for AB-FUBINACA and 0.1 ng/mL or 0.01 ng/mL for AB-
PINACA depending on the sample preparation technique. Combining the bias studies for 
the LLE in which bias was between 5% and 10% for most compounds, with the LOQ, 
having results in which 1 ng/mL were the lowest LOQ is reasonable due to the accuracy 
for the linear dynamic range being higher, therefore, concentrations that are on the lower 
end will have a greater % CV because the repeatability and reproducibility are not as 
anticipated. The SPE method having a LOQ of 1 ng/mL is not as expected due to the fact 
that the bias and precision for each compound was around 5%. 
 
Table 9. Limit of quantitation for urine. A comparative look at all three sample 
preparation techniques for each analytes LOQ value. 
 LOQ values (ng/mL) 
Compound Name LLE SPE SLE 
THC 1 1 0.75 
11-hydroxy-THC 1 1 0.5 
THCCOOH 1 1 0.5 
AB-FUBINACA 1 1 0.75 
AB-FUBINACA met 3 1 1 0.75 
AB-PINACA 1 1 1 
 
 
3.2.5 Other Validation Parameters 
 For all methods, each analyte signal was suppressed by the matrix (Table 10). The 
same two concentrations as recovery analysis were used for this study. The THC 
compounds and the synthetic cannabinoids were the least suppressed using the SLE 
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method. For all methods, suppression was the least for the synthetic cannabinoids. THC 
was the most suppressed using the LLE method, with the SPE and SLE having similar 
suppression results for THC. The SLE method was the most successful at removing 
components that affected suppression. 
 There was no carryover present for any of the analytes of interest during any of the 
validation studies for any of the methods.  
 
Table 10. Ion suppression or enhancement study results for urine. 
 10 ng/mL (%) 30 ng/mL (%) 
Compound Name LLE SPE SLE LLE SPE SLE 
THC -41.06 -36.11 -26.76 -50.71 -25.23 -28.79 
11-hydroxy-THC -23.21 -29.18 -19.78 -35.12 -21.19 -20.82 
THCCOOH -34.52 -34.91 -18.04 -43.09 -26.94 -20.80 
AB-FUBINACA -19.07 -25.37 -3.54 -29.03 -15.56 -10.73 
AB-FUBINACA met 3 -16.36 -27.13 -4.77 -23.41 -17.25 -5.37 
AB-PINACA -14.83 -18.12 1.81 -24.20 -10.77 -5.15 
 
For this study these drugs were broken down into three different mixes (Table 11). 
These compounds range from barbiturates, benzodiazepines, amphetamines, designer 
drugs, hallucinogens, opioids, analgesics, depressants, and novel psychoactive substances. 
For all 33 drugs studied as potential interferents, there was no interference present for any 
of the six analytes of interest or any of the internal standards. 
Another form of interference is from the matrix itself. Like the potential drug 
interferences, the components found in urine, such as the urea, creatinine, potassium and 
sodium ions to name a few, may interfere with the analytes of interest causing either 
suppression or enhancement of the analyte, along with the potential to mask the analyte 
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signal as well. The urine study showed matrix interferences that were less than 10% the 
area of the lowest calibrator for urine. However, due to the suppression levels, interferences 
from the matrix were impeding the analysis of these compounds.  
The last forms of interference assessed looked inward on the study to see if the 
internal standards interfere with the results in any way and if the analytes interfered with 
the internal standards. These results are important due to the analyte concentration being 
determined by the ratio of quant ion peak area to internal standard peak area. To assess if 
analyte effected the internal standard peak signal the highest calibrator was spiked into the 
urine and was extracted, however, no internal standard was added. For each analyte, there 
was no interference with the internal standards. To analyze if the analyte’s internal standard 
effected the analyte peak signal, blanks were run, in which the matrix was spiked with 
internal standard solution only. All analytes except AB-PINACA did not have interference 
with their respective internal standards. For AB-PINACA, AB-PINACA-d9 (the AB-
PINACA internal standard) did cause a peak in the blank samples. This signal was large 
enough that during the LOD studies, the peak area for the internal standard was the same 
as that of 0.01 ng/mL of AB-PINACA for the SPE and SLE methods, therefore the LOD 
was set at 0.1 ng/mL. For the LLE method, the internal standard interference was not as 
great allowing for the LOD to be 0.01 ng/mL for AB-PINACA. Due to this interference, 
for future studies, decreasing the concentration of AB-PINACA-d9 from 25 ng/mL would 
be advised. No other internal standard interferences were present. 
Dilution integrity evaluated the capability of taking a sample which is too 
concentrated and diluting down, while still getting accurate calculated concentrations. 
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These studies looked at a dilution factor of 1:10 and of 1:50, determined their overall bias 
and precision, and established if samples may be diluted by a factor of 1:10 and 1:50 if 
needed. All analytes are able to be diluted by a factor of 1:10 or 1:50. 
The final parameter assessed was the processed sample stability, assessing up to 72 
hrs for each analyte. All methods were stable up to 72 hrs for each of the six analytes of 
interest. 
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Table 11. Potential drug interference mixes. The three mix groups and the different 
potential drugs that would cause an interference that are commonly encountered during 




































Lysergic acid diethylamide (LSD) 
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3.3 Blood Results 
3.3.1 Calibration Range, Bias and Precision 
 A r2 value and a residuals plot were determined and created for each compound for 
each sample preparation technique. The r2 values needed to be 0.99 or greater (Table 12). 
The LLE method had the greatest r2 value for AB-FUBINACA metabolite 3 and THC. 11-
hydroxy-THC had the greatest value using the LLE and the SLE methods. While 
THCCOOH, AB-FUBINACA, and AB-PINACA had greater r2 values for the LLE and 
SPE methods. Similar to the urine method validation the residuals plots for THC, 11-
hydroxy-THC, and THCCOOH represented a linear range from 1 ng/mL to 50 ng/mL for 
all three sample preparation methods. Also like the urine data the LLE residuals plots for 
AB-FUBINACA, AB-FUBINACA metabolite 3, and AB-PINACA, and the residuals plots 
for AB-FUBINACA and AB-PINACA using the SLE method were beginning to resemble 
that of a quadric curve with the concentration range of 1 ng/mL to 50 ng/mL. The main 
difference between the urine and blood results was in that the synthetic cannabinoids 
residuals plots for the SPE method, and AB-FUBINACA metabolite 3 for the SLE method 
did not resemble a quadric curve (Figure 6). The scattered look of the residuals values for 
each calibration point around the zero value represents that of a linear curve, while the LLE 
and SLE plots for the synthetic cannabinoids residual values plotted against the 
concentration form more of a U-shape, resembling the beginning of a quadratic curve. With 
the r2 values being 0.995 or greater for all analytes over all three sample preparation 
techniques, using a linear curve fit is acceptable. Future studies of synthetic cannabinoids 
49 
may be best to analyze with an upper calibration point of 40 ng/mL or less. These values 
still fall above or near to what is typically reported for these compounds in the human body. 
 
Table 12. r2 values for blood. 
 r2 values 
Compound Name LLE SPE SLE 
THC 0.998 0.997 0.997 
11-hydroxy-THC 0.998 0.997 0.998 
THCCOOH 0.999 0.999 0.998 
AB-FUBINACA 0.999 0.999 0.997 
AB-FUBINACA met 3 0.999 0.998 0.996 
AB-PINACA 0.998 0.998 0.995 
 
 
For the bias studies completed on the blood matrix (Table 13), the SPE method 
had the best accuracy for all compounds except AB-FUBINACA metabolite 3. The SLE 
method was the most accurate for AB-FUBINACA metabolite 3, and more accurate 
compared to the LLE method for THC and THCCOOH. Except for analysis of AB-
FUBINACA metabolite 3 and THCCOOH utilizing the LLE method and analysis of AB-
PINACA utilizing the SLE method, all bias calculations were within ± 5%, with the 
above three situations having a bias within ± 7%. These values are all well within the ± 
20% validation criteria set by the ASB Guidelines. All further studies were not completed 
for blood analysis using the SLE method due to poor recovery of internal standards and 
analytes of the synthetic cannabinoids. Developing a new SLE method for the analysis of 




Figure 6. Residuals plot for AB-PINACA in blood using the SPE method. Unlike the 
LLE and SLE methods for blood, and the LLE, SPE, and SLE methods for urine, the AB-
PINACA residuals plots were not beginning to resemble that of a quadric curve, but 
represented that of the expected plot of a linear curve with the residual values being 


















Name LLE SPE SLE LLE SPE SLE LLE SPE SLE 
THC -3.28 -1.33 -2.90 8.46 7.27 11.90 5.53 5.08 6.87 
11-hydroxy-
THC 
-2.69 -0.04 -2.82 5.39 7.11 6.63 4.18 5.58 5.17 
THCCOOH -5.83 -3.53 -3.77 7.24 6.65 7.76 3.73 3.07 4.97 
AB-FUBINACA -3.49 -0.69 -3.97 4.22 3.76 3.86 1.78 2.14 2.61 
AB-FUBINACA 
met 3 
-6.67 -1.17 -0.84 7.84 6.75 11.01 2.91 6.75 7.48 
AB-PINACA -0.70 -0.21 -5.37 4.86 5.86 6.30 3.74 4.04 4.41 
 
3.3.2 Analyte Recovery in Blood Matrix 
 Similar to urine, 10 different negative lots of blood were analyzed at two different 
concentrations, 10 ng/mL and 30 ng/mL, for the recovery study (Table 14). The recovery 
for the THC compounds using the SPE method was below 10% recovery. The parent 
compound THC had a recovery that averaged 1.18% between the two concentrations, with 
the low concentration of 10 ng/mL having a recovery of 0.65%. LLE method had a 
recovery for THC that averaged 8.8%, and like the SPE method had a recovery value below 
10%. The two THC metabolites, 11-hydroxy-THC and THCCOOH, had greater recovery 
compared to the SPE method, with recovery values around 32% and 23% respectively. The 
synthetic cannabinoids had similar recovery values for both the LLE and SPE methods, 
with AB-PINACA having the highest recovery out of all analytes. The recovery was 
greatest for AB-PINACA using the LLE method, with a recovery averaging 64.5% while 
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the analyte recovery using the SPE method was 62%. Like AB-PINACA, AB-FUBINACA 
metabolite 3 had greater recovery utilizing the LLE method, with an average recovery of 
56.7%, while AB-FUBINACA had a greater recovery utilizing the SPE method for an 
average recovery of 59.2%. Recovery was similar between both concentrations with the 
higher concentration having slightly higher recovery.  
 
Table 14. Analyte recovery for blood. Two concentrations were analyzed for recovery 
analysis, a low concentration of 10 ng/mL and a high concentration of 30 ng/mL. 
 Recovery for 10 ng/mL (%) Recovery for 30 ng/mL (%) 
Compound Name LLE SPE SLE LLE SPE SLE 
THC 8.53 0.65 - 9.18 1.71 - 
11-hydroxy-THC 31.54 4.14 - 34.78 6.32 - 
THCCOOH 23.34 3.93 - 24.83 8.02 - 
AB-FUBINACA 52.57 61.25 - 58.71 57.17 - 
AB-FUBINACA met 3 53.08 43.68 - 60.43 60.58 - 
AB-PINACA 59.66 56.57 - 69.39 67.43 - 
 
3.3.3 LOD and LOQ for Blood Matrix 
For the blood matrix, there was variation within the LOD results for the two studied 
methods (Table 15). For THC and 11-hydroxy-THC, the LLE method had a much lower 
LOD compared to the SPE method. Utilizing the SPE method for analysis of THC and 11-
hydroxy-THC, the LOD was determined to be the same as the lowest calibrator, 1 ng/mL, 
for the linear dynamic range, while also being the same as the lower LOQ value. For the 
THC compounds using the LLE method of analysis, THC and THCCOOH had a lower 
LOD of 0.25 ng/mL compared to 11-hydroxy-THC, which had a LOD of 0.5 ng/mL. 
Compared to THC and 11-hydroxy-THC, AB-PINACA had a lower LOD with the SPE 
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method. The SPE method reached the initial goal of detection of 0.01 ng/mL. Assessing 
THCCOOH, AB-FUBINACA, and AB-FUBINACA metabolite 3, the LOD was the same 
for both the LLE and SPE methods. The LLE and SPE methods for blood results for the 
detection level mirror that of the urine results for all compounds except AB-PINACA. in 
which the LLE method has a lower detection level of 0.01 ng/mL while the SPE has a 
detection level of 0.1 ng/mL. Compared to the urine analysis for AB-PINACA, the blood 
results are opposite with the SPE method having a lower LOD of 0.01 ng/mL and the LLE 
detection limit being 0.1 ng/mL. 
Moving to the LOQ analysis, the LOQ determined for all six analytes using both 
the LLE and SPE method as the mode of analysis, the LOQ value was determined to be 1 
ng/mL which is the lowest calibrator in the linear dynamic range (Table 16). These results 
align with the SPE method for the analysis of THC, 11-hydroxy-THC, and THCCOOH 
considering the recovery of these compounds is below 10% for each analyte. With low 
recovery the amount of analyte reaching the detector creating a signal is decreased, 
therefore signal intensity is less and the likelihood of an accurate quantitative result for 
such low levels is reduced. For the LLE method as well, the recovery is below 35% for all 
THC compounds, creating a reduced chance of enough signal to accurately calculate the 
concentration at low levels. The LOQ of 1 ng/mL is unexpected for the synthetic 
cannabinoids for both sample preparation methods considering recovery was above 50% 
and a detection level of 0.01 ng/mL or 0.1 ng/mL was determined. However, at these lower 
concentrations such as 0.75 ng/mL or 0.5 ng/mL the %CV was always greater than the 
54 
allotted ± 20%, therefore quantitation is not possible. These quantitation results mirror that 
of the urine results for the LLE and SPE methods. 
Due to recovery studies determining the method developed for the SLE technique 
was not adequate for the analysis of the synthetic cannabinoids no LOD or LOQ results 
were performed. 
 
Table 15. Limit of detection for blood. Comparative look at the LLE, SPE, and SLE 
values for limit of detection. 
 LOD values (ng/mL) 
Compound Name LLE SPE SLE 
THC 0.25 1 - 
11-hydroxy-THC 0.5 1 - 
THCCOOH 0.25 0.25 - 
AB-FUBINACA 0.01 0.01 - 
AB-FUBINACA met 3 0.1 0.1 - 
AB-PINACA 0.1 0.01 - 
 
Table 16. Limit of quantitation for blood. 
 LOQ values (ng/mL) 
Compound Name LLE SPE SLE 
THC 1 1 - 
11-hydroxy-THC 1 1 - 
THCCOOH 1 1 - 
AB-FUBINACA 1 1 - 
AB-FUBINACA met 3 1 1 - 
AB-PINACA 1 1 - 
 
3.3.4 Ion Suppression, Carryover, Dilution Integrity, Processed Stability 
 All analytes of interest were suppressed using the LLE and SPE methods for 
extraction purposes (Table 17). The amount of suppression was greater with the SPE 
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method allowing for interpretation that the SPE method did not adequately remove and 
clean up the blood samples. This data is counter intuitive given the principle behind SPE 
is to produce cleaner extracts compared to LLE. The final extracts supplied enough of a 
hampering effect on the analyte signal to create large suppression effects on each analyte. 
Suppression was greatest for THC and 11-hydroxy-THC when the LLE method was used, 
with THCCOOH resulting in similar suppression as the synthetic cannabinoids for the LLE 
method. Utilizing the SPE method, the suppression for all three THC compounds was the 
greatest. AB-FUBINACA metabolite 3 had the least ion suppression for the LLE method 
while looking at all six compounds, while, when utilizing the SPE method the ion 
suppression resembled that more of the THC compounds. AB-FUBINACA had the least 
ion suppression for the SPE method. The synthetic cannabinoids had the least amount of 
suppression of all analytes. 
 As per the urine studies, no carryover was present for any analyte using any of the 
three sample preparation techniques.  
 When a sample has too great a concentration, the sample may be diluted up to a 
factor of 1:50. These dilution integrity studies were performed at a dilution factor of 1:10 
and 1:50, while the bias and precision were determined for each dilution factor. Both 
parameters were required to fall within ± 20%, which was accomplished at both 1:10 and 
1:50 dilution factors. 
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Table 17. Ion suppression for blood. 
 10 ng/mL (%) 30 ng/mL (%) 
Compound Name LLE SPE SLE LLE SPE SLE 
THC -49.49 -58.59 - -39.42 -51.49 - 
11-hydroxy-THC -29.29 -48.56 - -22.28 -47.17 - 
THCCOOH -41.72 -56.01 - -31.55 -53.12 - 
AB-FUBINACA -27.08 -31.52 - -12.59 -22.32 - 
AB-FUBINACA met 3 -19.55 -41.53 - -6.75 -34.11 - 
AB-PINACA -24.00 -32.50 - -18.72 -29.22 - 
 
For processed stability studies, THCCOOH, AB-FUBINACA, and AB-PINACA 
were all stable for 72 hrs for both the LLE and SPE method. THC and 11-hydroxy-THC 
were stable for 72 hrs using the SPE method. AB-FUBINACA metabolite 3 was stable for 
72 hrs using the LLE method. The shorter stability of 48 hrs for THC and 11-hydroxy-THC 
using the LLE method, and AB-FUBINACA metabolite 3 using the SPE method all fell 
just outside the ± 20% ratio range of the quant ion:internal standard ion. 
 
3.3.5 Interferences 
 Using 33 different drugs placed in three different mixes, interference studies were 
completed (Table 11). As with urine, no interferences were caused by any of these analytes 
while utilizing any of the sample preparation techniques. The highest calibrator did not 
interfere with the internal standard and all internal standards but AB-PINACA did not 
interfere with the analytes. As with urine, the AB-PINACA internal standard caused a peak 
signal for AB-PINACA analyte. This had the most baring on the LOD, in which the area 
for the peak at 0.01 ng/mL for the LLE method was the same as the area for the internal 
standard in the sample spiked only with internal standard. Therefore, the LOD was 
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determined to be 0.1 ng/mL. While the internal standard did create a peak in the blank 
sample spiked with internal standard for the SPE method, the peak area was smaller than 
that of the 0.01 ng/mL peak allowing for a detection level of 0.01 ng/mL to be set. 
 For matrix interference studies, all analytes had interferences less than 10% the 
average area of the lowest calibrator. One issue with completing the blood validation was 
acquiring negative blood samples for validation analysis. All blood lots were screened by 
gas chromatography – mass spectrometry (GC/MS) running a full screen, monitoring for 
any analytes present in the blood. A targeted analysis using the LC-MS/MS was then 
completed due to the lower LODs associated with targeted analysis. Due to the LLE 
method validation occurring first, all blood lots were screened using this method for a 
consistent screening process throughout the study. The most commonly encountered 
substances in the blood screen was THCCOOH and an endogenous peak with the same 
retention time. The endogenous interference was a large peak at 3.49 min that typically 
appeared with a twin peak at a retention time of 3.58 min (Figure 7). Blood lots containing 





Figure 7. Negative blood sample with THCCOOH interference. The peak at 3.50 min 
is the same retention time as THCCOOH, therefore creating an unusable blood sample.  
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4. DISCUSSION 
4.1 Method Development 
 To be able to compare each sample preparation technique to one another the amount 
of sample was held constant for all three sample preparation techniques. When determining 
if the same sample preparation method could be used for both blood and urine the matrix 
volume was kept the same along with keeping all steps the same between the two matrices. 
All method development began with blood as the matrix of interest due to the complexities 
of blood compared to urine. Once the method had been developed with blood the method 
was then transferred to urine. 
This process was acceptable for developing methods for two of the three sample 
preparation methods. When developing the SLE method, this process yielded undesirable 
results. Analysis of validation parameters began with calibration model, bias, and 
precision, in which all six analytes had acceptable residual plots, r2 values, bias 
percentages, and precision values. When moving to analyte recovery studies, the recovery 
results for AB-FUBINACA metabolite 3 were inconsistent between the 10 different blood 
lots. Matrix effects on AB-FUBINACA metabolite 3 were more significant for blood lots 
that had been stored in a refrigerator or freezer for longer periods of time or older blood 
samples. Due to AB-FUBINACA metabolite 3 not being determined to be a metabolite 
found in blood and only urine, the compound was removed from the analyzed compounds 
for blood. When further recovery studies were completed for the SLE method on blood the 
recovery of the ratio between the analyte ions and the internal standard ions for the 
synthetic cannabinoids was not the same as the neat solutions, causing the recovery studies 
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to fail for AB-FUBINACA and AB-PINACA. With this development it was determined 
that analysis on blood required a new SLE method. All parameters for urine were 
completed. 
When developing each method, literature reviews supplied methods for the 
extraction of THC, 11-hydroxy-THC, and THCCOOH together and methods for the 
extraction of synthetic cannabinoids, while finding methods that extracted THC 
compounds and synthetic cannabinoids together in one method were not found or 
published. As a result, methods were typically developed around extraction of THC and its 
metabolites due to these compounds having lower signal intensity and the synthetic 
cannabinoids more readily extracting from the matrices. 
 
4.1.1 Liquid-Liquid Extraction 
 The initial method development began with 200 µL of blood. The first trials also 
began with 10% glacial acetic acid and a hexane:ethyl acetate (90:10) organic solvent 49. 
These samples were reconstituted in 100 µL of 0.1% formic acid in DI water after the 
organic layer was removed and dried down. Analysis on a KinetexÒ F5, 2.6 µm 100 Å, 50 
x 3.0 mm column (Phenomenex, Torrance, CA, USA) showed the majority of the analytes 
of interest were not extracted from the matrix. AB-FUBINACA, AB-PINACA and AB-
FUBINACA metabolite 3 were the only analytes that were extracted and able to be viewed 
on the chromatogram. All the working stock solutions were run as neat solutions to ensure 
all compounds were present and analysis showed a chromatogram with all analytes, 
confirming that the initial extraction method only extracted three analytes. Next steps 
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included increasing the acidity by using 20% glacial acetic acid, using 100% hexane, 100% 
dichloromethane (DCM), and 90:10 hexane:ethyl acetate. Once the organic layer was 
removed and dried down, all samples were reconstituted in 0.1% formic acid in DI 
water:ACN (70:30), due to this ratio being the starting mobile phase conditions. The 100% 
hexane trial did not extract THCCOOH. Using 20% glacial acetic acid and 90:10 
hexane:ethyl acetate extracted all compounds; however, the signal intensity was weak. All 
analytes were extracted using 100% DCM and 20% glacial acetic acid, however there was 
significant peak tailing. Using the 100% DCM and 20% glacial acetic acid method, another 
trial was run on both blood and urine and the XBridgeÒ C18 column (Waters Corporation, 
Milford, MA, USA) was used, which gave Gaussian peaks and better resolution of 11-
hydroxy-THC and THCCOOH, while the resolution of AB-PINACA and AB-FUBINACA 
metabolite 3 was decreased as compared to the F5 column. However, the lower 
concentration levels had weak peak signal intensity. Another drawback using DCM was 
the organic layer was the bottom layer, therefore removal of the organic layer required the 
pipette tip moving through the blood layer, creating a final organic solution with residual 
amounts of blood in every sample. To remove the issue with DCM being the bottom layer 
and creating better extraction results of the compounds at lower levels, the acid was 
changed and the ratio of hexane:ethyl acetate was adjusted. For these trials 5% phosphoric 
acid was also evaluated 50 along with 90:10 hexane:ethyl acetate and 80:20 hexane:ethyl 
acetate. These trials had varying results with accuracy of the synthetic cannabinoids and 
which THC compounds were extracted. A literature search revealed a multitude of methods 
using 500 to 1,000 µL of matrix for extraction and reconstituting in 100 µL of 
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reconstitution solution to increase the signal intensity of THC and its metabolites. The 
volume of blood and urine was then increased to 400 µL. The final method trials involved 
changing the organic solvent to include an ether, one trial involved diethyl ether while two 
other trials used MTBE 50–52 and evaluating 5% phosphoric acid and 5% glacial acetic acid. 
The diethyl ether did not extract THC or its metabolites, with the chromatograms 
resembling those of solvent blanks for the THC compounds. While both the phosphoric 
acid and glacial acetic acid extracted all compounds when combined with 80:10:10 
hexane:ethyl acetate:MTBE the final method settled upon glacial acetic acid due to better 
signal for THC and its metabolites. If this study was focusing on synthetic cannabinoids 
only using phosphoric acid would be the better acid solvent due to greater signal intensity 
for the synthetic cannabinoids. 
 Due to the viscosity of the blood or urine being similar to the organic solvent, a 
freezing step was added before the organic layer was removed. This idea was adopted from 
The Center for Forensic Science Research and Education LLE method. By freezing the 
samples, the matrix layer would be either frozen solid or cold enough that it became more 
viscous allowing for removal of the organic layer to be more efficient. If any matrix was 
removed then pipetted back into the vial the emulsion that formed was decreased compared 
to no freezing step. 
Comparing the blood and urine sample preparation, the urine samples took longer 
to freeze compared to the blood samples. While the freezing process was not included to 
increase the extraction efficiency but to increase the yield of organic layer removed while 
decreasing chances of matrix contamination while pipetting out the organic layer, the 
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freezing step may be removed or shortened to decrease the total time. Due to unexpected 
circumstances, blood samples were left in the freezer for 24 hrs before the organic layer 
was removed. These samples were then analyzed and the data interpreted. The calibration 
curve, three QCS, and other samples being analyzed passed for accuracy in calculating the 
expected concentration. Therefore, samples may be left in the freezer for 24 hrs before 
removing the organic layer and completing analysis. 
 
4.1.2 Solid Phase Extraction 
 Styre ScreenÒ THC columns were used for the SPE method. These columns were 
designed to be specific to THC, 11-hydroxy-THC, and THCCOOH. The columns were 3 
mL columns with 60 mg sorbent bed composed of ultra clean, highly cross-linked styrene 
and divinylbenzene copolymer 48. The particle size ranged from 10 to 20 µm on average 
48. The columns were designed to remove the conditioning step from a traditional SPE 
method, allowing the sample to be loaded directly onto the column. The developed method 
was modified from the application note, which was supplied along with the columns, for 6 
mL columns with 100 mg sorbent bed 48. The matrix volume was reduced to 400 µL and 
the solvents were scaled appropriately according to the ratios used in the application note. 
The application note included a decanting step after the samples were centrifuged, which 
was removed for the final method due to the possibility of analyte loss during the transfer 
steps. Due to THC having an affinity to bind to glass, removing as many solvent transfer 
steps as possible increased the possibility of THC or any compound not to be left in a test 
tube and not extracted into the final solution that reached the LC autosampler. 
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4.1.3 Supported Liquid Extraction 
 For extraction, 1 mL IsoluteÒ SLE+ columns from Biotage were used. The 
columns are composed of diatomaceous earth, silicon dioxide, and quartz 43. Method 
development began with running trials of different application notes supplied by Biotage. 
The application notes focused on either extracting THC and its metabolites or extracting 
synthetic cannabinoids and their metabolites. Since SLE is built around the principles of 
LLE while adding a column to increase removal of matrix interferences and other 
interferences, the first step was to transfer the LLE method to the SLE columns. Using 1 
mL columns, the initial volume of pretreated matrix could not exceed 1 mL. This was to 
not oversaturate the column which could lead to break through or decreased recovery due 
to matrix and interferences not binding to the column materials. Therefore, the 20% glacial 
acetic acid and DI water were combined into a 5% glacial acetic acid solution that the blood 
and urine were pretreated with. When the acid was added to the blood clots began to form 
which hindered the matrix from absorbing into the column beds and later hindered the 
absorption of the organic solvent into and through the column. Other trials were tried in 
which acid concentration was adjusted or the acid was changed. In the end, the samples 
were centrifuged causing the clots to sink to the bottom the of test tube and the supernatant 
could be removed. 
 The organic solvent was assessed to see if separating the three organic solvents, 
hexane, ethyl acetate and MTBE would increase recovery. A number of trials where 50:50 
hexane:ethyl acetate followed by 100% MTBE were assessed. The final parameters for the 
method of 5% glacial acetic acid and 80:10:10 hexane:ethyl acetate: MTBE were chosen 
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due to these parameters having the best recovery of the THCCOOH and AB-FUBINACA 
metabolite 3 compounds, which were the analytes that were the most complicated analytes 
to extract. 
 
4.1.4 Technique Comparison 
Further comparison parameters include the amount of time each preparation 
technique required, the number of resources, the amount of solvents consumed, and the 
cost associated with supplies. Each technique required time spent moving through the 
method steps. The LLE method took the most amount of time, with the average number of 
samples taking 4 hrs from start of preparation to the samples being placed in the 
autosampler. The 4 hrs can be reduced by removing or decreasing the freezing time. The 
SPE method averaged 2 hrs for sample preparation while the SLE method consumed the 
least amount of time, taking 1 hr to complete. 
When comparing the resources used, the preparation of mobile phases and 
reconstitution solution was excluded, due to their being no difference in volumes between 
the sample preparation techniques. The SPE method used the greatest number of different 
solvents with six. The LLE and SLE used less solvents, five for the LLE and four for the 
SLE. When totaling the solvent volumes consumed for a single sample the SLE method 
used the most solvent, with a total volume of 6.2 mL. The SPE used the least total volume 
of 4.5 mL of solvent during the extraction process. The LLE method was the least 
expensive technique, while the SLE and SPE methods were more expensive due to the cost 
of the columns. The SPE columns were the most expensive per column compared to the 
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SLE columns. Due to the solvents and glassware being similar between all three sample 
preparation techniques, the cost involved with purchasing these solvents, along with test 




LLE, SPE, and SLE methods were developed for the analysis and quantitation of 
THC, 11-hydroxy-THC, THCCOOH, AB-FUBINACA, AB-FUBINACA metabolite 3, 
and AB-PINACA. For the analysis of THC, synthetic cannabinoids, and their metabolites 
in urine all three sample preparation techniques were acceptable for forensic toxicology 
analysis. Looking at the validation parameters and time consumed, the preferred method 
for analysis is the SLE method. This is due to the reduced suppression effects, reduced 
matrix effects, the lower LOQ, and reduced sample preparation time. For blood, both the 
LLE and SPE method were acceptable for forensic toxicology analysis, however looking 
at validation parameters, the preferred method for blood analysis is the LLE method due to 
the increased analyte recovery, the lower number of different solvents, the reduced 
suppression and matrix effects. For the most cost-effective method with suitable results, 











6. FUTURE WORK 
6.1 Additional Sample Preparation Techniques 
 One goal of this project was to use the same sample preparation method for both 
blood and urine. This was able to be accomplished for the LLE and SPE methods, however 
the SLE method was not adequate enough the validate the method for blood. A further 
study into creating a SLE method that can be used for both blood and urine in which both 
matrices are able to be fully validated. Work was begun to determine a SLE method in 
which blood could be fully validated and completing this work to ensure that this new 
method could be used for the analysis of THC, 11-hydroxy-THC, THCCOOH, AB-
FUFINACA, AB-FUBINACA metabolite 3, and AB-PINACA in human whole blood and 
urine would fully complete this comparison of these various sample preparation 
techniques. 
Looking into different SPE columns from UCT as well as from other companies, 
such as Waters, Biotage, and Tecan to see if better results are possible. Seeing if the 
addition of adding a phospholipid cartridge before using the SPE or SLE cartridges would 
be interesting to see if this could clean up the sample more and give a better limit of 
detection for the THC compounds. Also, looking into modifying the UCT Styre ScreenÒ 
THC columns method to see if changing the sample pretreatment, the wash solution, or 
elution solution would aid in greater recovery of the THC compounds, especially since 
these columns are designed specifically for THC. 
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Another future project would be looking at a different LLE method to compare 
results. One method involves the DCM method mentioned above where the top layer is 
aspirated off matrix instead of pipetting through the matrix layer. 
 
6.2 Additional Compounds 
 Adding in more metabolites of the synthetic cannabinoids such as AB-PINACA 
pentanoic acid and AB-FUBINACA metabolite 2a or metabolite 4. Including the analysis 
of newer synthetic cannabinoids found in case reports to determine if the three sample 
preparation methods also extract these compounds or if the sample preparation methods 
would need to be modified for analysis. Adding in additional phytocannabinoids, such as 






APPENDIX A: STANDARD REAGENTS 
Table A. Certified Reference Material Lot Numbers. All reference material was 
purchased from Cayman Chemical. 
THC (1 mg/mL) 0530060 0515871 
11-hydroxy-THC (1 mg/mL) 0504656 0504398 
THCCOOH (1 mg/mL) 0497428 - 
AB-FUBINACA (1 mg/mL) 0468160 0521258 
AB-FUBINACA metabolite 3 (1 mg/mL) 0471112-9 0534117-2 
AB-PINACA (1 mg/mL) 0468078 0534770 
THC-d3 (100 µg/mL) 0481952 0481952 
11-hydroxy-THC-d3 (100 µg/mL) 0504666 - 
11-nor-9-caborxy-THC-d3 (100 µg/mL) 0428976-7 0428976-10 
AB-FUBINACA-d4 (1 mg/mL) 0516865-1 - 
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